title: [Trisomy 21 and cancers].
abstract: Patients with trisomy 21, still called Down's syndrome (DS), present a particular tumoral profile compared to the general population with an increased incidence of leukaemia in the childhood and a low risk of solid cancer in the adulthood. DS children indeed present a 50-fold risk of developing a leukaemia compared to age-matched non-trisomic children and most of them develop a specific myelodysplasic disorder called transient myelodysplasic disorder. In spite of the low incidence of solid tumors, some are very rare as breast cancer, nephroblastoma, neuroblastoma and medulloblastoma, whereas the others remain more frequent as retinoblastoma, lymphoma and gonadal and extragonadal germ cell tumours. In this review, we present possible mechanisms which can favour, or on the contrary repress the formation and progression of tumours in DS patients, which are related to gene effect dosage of oncogenes or tumour repressors on chromosome 21, tumour angiogenesis, apoptosis and epithelial cell-stroma interactions.
authors.affiliation: Université Clermont 1, UFR médecine, cytologie histologie embryologie cytogénétique, 63001 Clermont-Ferrand, France.
authors.forename: W
authors.initials: W
authors.lastname: Ayed
authors.forename: L
authors.initials: L
authors.lastname: Gouas
authors.forename: F
authors.initials: F
authors.lastname: Penault-Llorca
authors.forename: A
authors.initials: A
authors.lastname: Amouri
authors.forename: A
authors.initials: A
authors.lastname: Tchirkov
authors.forename: P
authors.initials: P
authors.lastname: Vago
mesh_terms: D004314:Down Syndrome / Q000150:complications* / Q000235:genetics; D006801:Humans; D009369:Neoplasms / Q000453:epidemiology / Q000209:etiology* / Q000235:genetics